Company news
Oxford Biomedica Plc (LSE:OXB) news
Every Oxford Biomedica Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Oxford Biomedica : Half Year Trading Update and Notice of Results
August 7, 2026
OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme
July 16, 2026
Admission to trading application
June 17, 2026
OXB Capital Markets Event
June 2, 2026
OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)
May 8, 2026
Launch of viral vector fast-track offering
April 13, 2026
Grant of Awards
April 8, 2026
2026 Annual General Meeting notification
March 30, 2026
Preliminary results for the year ended 31 Dec 2025
March 26, 2026
Licensing agreement with VVMF
March 18, 2026
Admission to Trading
March 9, 2026
Admission to Trading Application
March 4, 2026
Capital Markets Day and investor conferences
March 3, 2026
Total Voting Rights
March 2, 2026
Response to Rule 2.8 Announcement
February 25, 2026
Disclosure Table
February 25, 2026
Rule 2.8 Announcement
February 25, 2026
Full year Trading Update and Notice of Results
February 24, 2026
Rule 2.9 Announcement
February 19, 2026
Extension of PUSU Deadline
February 11, 2026
Multi-year supply agreement with BMS
February 4, 2026
Response to press speculation
January 14, 2026
Block Listing Return
January 2, 2026
PDMR Dealing
December 8, 2025
Holding(s) in Company
November 3, 2025
OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category
October 29, 2025
OXB honoured at 2025 CDMO Leadership Awards Europe
October 29, 2025
OXB to participate in upcoming investor conferences and events
October 27, 2025
OXB to participate in investor conferences
October 27, 2025
Director/PDMR Shareholding
October 20, 2025
Board Change
October 20, 2025
OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina
October 7, 2025
Acquisition of US viral vector facility
October 7, 2025
Interim Results for 6 months ended 30 June 2025
September 23, 2025
PDMR Dealings
August 22, 2025
Admission of Shares and Total Voting Rights
August 20, 2025
Results of Placing
August 15, 2025
Proposed Placing of New Ordinary Shares
August 14, 2025
OXB Secures New Loan Facility with Oaktree
August 1, 2025
Half Year Trading Update
July 28, 2025
Director Declaration
July 2, 2025
Block listing Interim Review
July 1, 2025
OXB completes acquisition of US subsidiary
June 23, 2025
Result of Annual General Meeting
June 11, 2025
AGM Update
June 11, 2025
Block Listing Application
June 5, 2025
OXB Highlights the Launch of its Innovation and Technology Excellence Board
June 3, 2025
OXB Launches Advisory Board
June 3, 2025
Grant of options
May 16, 2025
OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 9, 2025